Genotype and age at parkinson disease diagnosis

International Journal of Molecular Epidemiology and Genetics

Volumn 4, Issue 1, 2013, Pages 61-69

  Searles Nielsen, Susan ^a   Bammler, Theo K ^a   Gallagher, Lisa G ^a   Farin, Federico M ^a   Longstreth, W T ^a   Franklin, Gary M ^a   Swanson, Phillip D ^a   Checkoway, Harvey ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arachidonic acid; CYP2J2 protein; CYP3A7 protein; Divalent metal transporter 1; GSTM5 protein; Idiopathic parkinson disease; Linoleic acid; SLC11A2 protein

Indexed keywords

CYTOCHROME P450 2J2; MICRORNA;

ADULT; AGE; AGED; ALLELE; ARTICLE; CAUCASIAN; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DNA EXTRACTION; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; INFLAMMATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; POPULATION BASED CASE CONTROL STUDY; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STRUCTURED QUESTIONNAIRE; SURVIVAL;

EID: 84875405418     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002; 55: 25-31.
2. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022.
3. Wright Willis A, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Predictors of survival in patients with Parkinson disease. Arch Neurol 2012; 69: 601-607.
4. Bové J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012; 211: 51-76.
5. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE. Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res 2006; 6: 261-281.
6. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP; 23andMe Genetic Epidemiology of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Parkinson's Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet 2012; 8: e1002548.
7. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991; 337: 1321-1324.
8. Sloan M, Alegre-Abarrategui J, Wade-Martins R. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem Soc Trans 2012; 40: 1080-1085.
9. Gómez-Suaga P, Hilfiker S. LRRK2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy. Autophagy 2012; 8: 692-693.
10. Niu J, Yu M, Wang C, Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 2012; 122: 650-658.
11. Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sónchez J, Mittag F, Büchel F, Sharma M, Gibbs JR, Schulte C, Moskvina V, Durr A, Holmans P, Kilarski LL, Guerreiro R, Hernandez DG, Brice A, Ylikotila P, Stefánsson H, Majamaa K, Morris HR, Williams N, Gasser T, Heutink P, Wood NW, Hardy J, Martinez M, Singleton AB, Nalls MA; for the International Parkinson's Disease Genomics Consortium (IPDGC) and The Wellcome Trust Case Control Consortium 2 (WTCCC2).Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet 2012; 21: 4996-5009.
12. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011; 26 Suppl 1: S1-S58.
13. Auyeung M, Tsoi TH, Mok V, Cheung CM, Lee CN, Li R, Yeung E. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol Neurosurg Psychiatry 2012; 83: 607-611.
14. Duarte J, García Olmos LM, Mendoza A, Clavería LE. The natural history of Parkinson's disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up). Acta Neurol Scand 2012 Sep 7.
15. Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66: 1353-1358.
16. Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T; PROGENI Investigators, Coordinators and Molecular Genetic Laboratories; GenePD Investigators,Coordinators and Molecular Genetic Laboratories. Genomewide association study for onset age in Parkinson disease. BMC Med Genet 2009; 10: 98.
17. Wilk JB, Lash TL. Risk factor studies of age-atonset in a sample ascertained for Parkinson disease affected sibling pairs: a cautionary tale. Emerg Themes Epidemiol 2007; 4: 1.
18. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155: 732-738.
19. Searles Nielsen S, Checkoway H, Butler RA, Nelson HH, Farin FM, Longstreth WT Jr, Franklin GM, Swanson PD, Kelsey KT. LINE-1 DNA Methylation, Smoking and Risk of Parkinson's Disease. J Parkinsons Dis 2012; 2: 303-308.
20. Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, Hayward C, Volpato CB, Pattaro C, Vitart V, Wright A, Campbell H, Klein C, Pramstaller PP. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011; 43: 246-250.
21. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and Candidate Gene Information into Functional SNP Selection for Genetic Association Studies. Nucleic Acids Res 2009; 37: W600-W605.
22. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005; 77: 685-693.
23. Berlin DS, Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. Pharmacogenet Genomics 2011; 21: 308-311.
24. Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, Bièche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts C, Loriot MA. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009; 37: 1528-1538.
25. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 2011; 339: 451-463.
26. Gómez-Ramos A, Díaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003; 71: 863-870.
27. Cui PH, Lee AC, Zhou F, Murray M. Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. Br J Pharmacol 2010; 159: 1440-1449.
28. Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 2013; 22: 608-20.
29. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC. Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease. J Parkinsons Dis 2012; 2: 321-331.
30. Nelson PT, Wang WX, Rajeev BW. MicroRNAs(miRNAs) in neurodegenerative diseases. Brain Pathol 2008; 18: 130-138.
31. Junn E, Mouradian MM. MicroRNAs, in neuro degenerative diseases and their therapeutic potential. Pharmacol Ther 2012; 133: 142-150.
32. Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci 1999; 49: 156-164.
33. Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71: 776-784.
34. Zaheer F, Slevin JT. Trichloroethylene and Parkinson disease. Neurol Clin 2011; 29: 657-665.
35. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997; 324: 25-28.
36. Roth JA, Garrick MD. Iron interactions and other biological reactions mediating the physiological and toxic actions of manganese. Biochem Pharmacol 2003; 66: 1-13.
37. Wright Willis A, Evanoff BA, Lian M, Galarza A, Wegrzyn A, Schootman M, Racette BA. Metalemissions and urban incident Parkinson disease:a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010; 172: 1357-1363.
38. He Q, Du T, Yu X, Xie A, Song N, Kang Q, Yu J,Tan L, Xie J, Jiang H. DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett 2011; 501: 128-131.
39. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF,Maher NE, Wilk JB, Sullivan KM, Slater KM,Saint-Hilaire MH, Feldman RG, Suchowersky O,Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet 2002; 70: 1089-1095.
40. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC,Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA Jr, Goetz CG, Mastaglia F, Stajich JM, Gibson RA, Middleton LT, Saunders AM, Scott BL,Small GW, Nicodemus KK, Reed AD, Schmechel DE, Welsh-Bohmer KA, Conneally PM,Roses AD, Gilbert JR, Vance JM, Haines JL,Pericak-Vance MA. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002; 70: 985-993.
41. Pankratz N, Uniacke SK, Halter CA, Rudolph A,Shults CW, Conneally PM, Foroud T, Nichols WC; Parkinson Study Group. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology 2004; 62: 1616-1618.
42. Noureddine MA, Qin XJ, Oliveira SA, Skelly TJ,van der Walt J, Hauser MA, Pericak-Vance MA,Vance JM, Li YJ. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet 2005; 117: 27-33.
43. Oliveira SA, Li YJ, Noureddine MA, Zuchner S,Qin X, Pericak-Vance MA, Vance JM. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am J Hum Genet 2005; 77: 252-264.
44. Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH,Tan LC, An XK, Chen CM, Fook-Chong S, Lu CS.LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1022-1023.
45. Butler MW, Burt A, Edwards TL, Zuchner S,Scott WK, Martin ER, Vance JM, Wang L. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet 2011; 75:201-210.